Hypoxia marker labeling in tumor biopsies: Quantification of labeling variation and criteria for biopsy sectioning

Donald E. Thrall, Gary Rosner, Chieko Azuma, Margaret C. McEntee, James A. Raleigh

Research output: Contribution to journalArticle

Abstract

Background and purpose: The error associated with using biopsy-based methods for assessing parameters reflective of the tumor microenvironment depends on the variability in distribution of the parameter throughout the tumor and the biopsy sample. Some attention has been given to intratumoral distribution of parameters, but little attention has been given to their intrabiopsy distribution. We evaluated the intrabiopsy distribution of CCI- 103F, a 2-nitroimidazole hypoxia marker. Materials and methods: The hypoxia marker CCI-103F was studied in dogs bearing spontaneous solid tumors. Two biopsies were taken from each of seven tumors, for a total of 14 biopsies. Biopsies were serially sectioned and four to six contiguous slides from each 100-150 μm of the biopsy were used to formulate the best estimate of CCI- 103F labeled area throughout the biopsy sample. One, two or four slides were then randomly selected from each biopsy and the labeled area, based on this limited sample, was compared to the estimate obtained from counting all available slides. Random sampling of slides was repeated 1000 times for each biopsy sample. Results: CCI-103F labeling variance throughout the biopsy decreased as the estimated overall labeled area in the biopsy decreased. The error associated with estimating the overall labeled area in a biopsy from a randomly selected subset of slides decreased as the number of slides increased, and as the overall labeled area in the biopsy decreased. No minimally labeled biopsy was classified as unlabeled based on limited sampling. Conclusion: With regard to CCI-103F labeling, quantification of the labeled area in four randomly selected slides from a biopsy can provide, in most biopsies, an estimate of the labeled area in the biopsy within an absolute range of ±0.05.

Original languageEnglish (US)
Pages (from-to)171-176
Number of pages6
JournalRadiotherapy and Oncology
Volume44
Issue number2
DOIs
StatePublished - Aug 1997
Externally publishedYes

Fingerprint

Biopsy
Neoplasms
Hypoxia
Tumor Microenvironment
CCI 103F
Dogs

Keywords

  • Canine tumors
  • CCI- 103F
  • Hypoxia
  • Hypoxia markers
  • Nitroimidazole markers
  • Sampling error

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Urology

Cite this

Hypoxia marker labeling in tumor biopsies : Quantification of labeling variation and criteria for biopsy sectioning. / Thrall, Donald E.; Rosner, Gary; Azuma, Chieko; McEntee, Margaret C.; Raleigh, James A.

In: Radiotherapy and Oncology, Vol. 44, No. 2, 08.1997, p. 171-176.

Research output: Contribution to journalArticle

Thrall, Donald E. ; Rosner, Gary ; Azuma, Chieko ; McEntee, Margaret C. ; Raleigh, James A. / Hypoxia marker labeling in tumor biopsies : Quantification of labeling variation and criteria for biopsy sectioning. In: Radiotherapy and Oncology. 1997 ; Vol. 44, No. 2. pp. 171-176.
@article{926a77c042dc4c5c96df8ba8f9129929,
title = "Hypoxia marker labeling in tumor biopsies: Quantification of labeling variation and criteria for biopsy sectioning",
abstract = "Background and purpose: The error associated with using biopsy-based methods for assessing parameters reflective of the tumor microenvironment depends on the variability in distribution of the parameter throughout the tumor and the biopsy sample. Some attention has been given to intratumoral distribution of parameters, but little attention has been given to their intrabiopsy distribution. We evaluated the intrabiopsy distribution of CCI- 103F, a 2-nitroimidazole hypoxia marker. Materials and methods: The hypoxia marker CCI-103F was studied in dogs bearing spontaneous solid tumors. Two biopsies were taken from each of seven tumors, for a total of 14 biopsies. Biopsies were serially sectioned and four to six contiguous slides from each 100-150 μm of the biopsy were used to formulate the best estimate of CCI- 103F labeled area throughout the biopsy sample. One, two or four slides were then randomly selected from each biopsy and the labeled area, based on this limited sample, was compared to the estimate obtained from counting all available slides. Random sampling of slides was repeated 1000 times for each biopsy sample. Results: CCI-103F labeling variance throughout the biopsy decreased as the estimated overall labeled area in the biopsy decreased. The error associated with estimating the overall labeled area in a biopsy from a randomly selected subset of slides decreased as the number of slides increased, and as the overall labeled area in the biopsy decreased. No minimally labeled biopsy was classified as unlabeled based on limited sampling. Conclusion: With regard to CCI-103F labeling, quantification of the labeled area in four randomly selected slides from a biopsy can provide, in most biopsies, an estimate of the labeled area in the biopsy within an absolute range of ±0.05.",
keywords = "Canine tumors, CCI- 103F, Hypoxia, Hypoxia markers, Nitroimidazole markers, Sampling error",
author = "Thrall, {Donald E.} and Gary Rosner and Chieko Azuma and McEntee, {Margaret C.} and Raleigh, {James A.}",
year = "1997",
month = "8",
doi = "10.1016/S0167-8140(97)01931-2",
language = "English (US)",
volume = "44",
pages = "171--176",
journal = "Radiotherapy and Oncology",
issn = "0167-8140",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Hypoxia marker labeling in tumor biopsies

T2 - Quantification of labeling variation and criteria for biopsy sectioning

AU - Thrall, Donald E.

AU - Rosner, Gary

AU - Azuma, Chieko

AU - McEntee, Margaret C.

AU - Raleigh, James A.

PY - 1997/8

Y1 - 1997/8

N2 - Background and purpose: The error associated with using biopsy-based methods for assessing parameters reflective of the tumor microenvironment depends on the variability in distribution of the parameter throughout the tumor and the biopsy sample. Some attention has been given to intratumoral distribution of parameters, but little attention has been given to their intrabiopsy distribution. We evaluated the intrabiopsy distribution of CCI- 103F, a 2-nitroimidazole hypoxia marker. Materials and methods: The hypoxia marker CCI-103F was studied in dogs bearing spontaneous solid tumors. Two biopsies were taken from each of seven tumors, for a total of 14 biopsies. Biopsies were serially sectioned and four to six contiguous slides from each 100-150 μm of the biopsy were used to formulate the best estimate of CCI- 103F labeled area throughout the biopsy sample. One, two or four slides were then randomly selected from each biopsy and the labeled area, based on this limited sample, was compared to the estimate obtained from counting all available slides. Random sampling of slides was repeated 1000 times for each biopsy sample. Results: CCI-103F labeling variance throughout the biopsy decreased as the estimated overall labeled area in the biopsy decreased. The error associated with estimating the overall labeled area in a biopsy from a randomly selected subset of slides decreased as the number of slides increased, and as the overall labeled area in the biopsy decreased. No minimally labeled biopsy was classified as unlabeled based on limited sampling. Conclusion: With regard to CCI-103F labeling, quantification of the labeled area in four randomly selected slides from a biopsy can provide, in most biopsies, an estimate of the labeled area in the biopsy within an absolute range of ±0.05.

AB - Background and purpose: The error associated with using biopsy-based methods for assessing parameters reflective of the tumor microenvironment depends on the variability in distribution of the parameter throughout the tumor and the biopsy sample. Some attention has been given to intratumoral distribution of parameters, but little attention has been given to their intrabiopsy distribution. We evaluated the intrabiopsy distribution of CCI- 103F, a 2-nitroimidazole hypoxia marker. Materials and methods: The hypoxia marker CCI-103F was studied in dogs bearing spontaneous solid tumors. Two biopsies were taken from each of seven tumors, for a total of 14 biopsies. Biopsies were serially sectioned and four to six contiguous slides from each 100-150 μm of the biopsy were used to formulate the best estimate of CCI- 103F labeled area throughout the biopsy sample. One, two or four slides were then randomly selected from each biopsy and the labeled area, based on this limited sample, was compared to the estimate obtained from counting all available slides. Random sampling of slides was repeated 1000 times for each biopsy sample. Results: CCI-103F labeling variance throughout the biopsy decreased as the estimated overall labeled area in the biopsy decreased. The error associated with estimating the overall labeled area in a biopsy from a randomly selected subset of slides decreased as the number of slides increased, and as the overall labeled area in the biopsy decreased. No minimally labeled biopsy was classified as unlabeled based on limited sampling. Conclusion: With regard to CCI-103F labeling, quantification of the labeled area in four randomly selected slides from a biopsy can provide, in most biopsies, an estimate of the labeled area in the biopsy within an absolute range of ±0.05.

KW - Canine tumors

KW - CCI- 103F

KW - Hypoxia

KW - Hypoxia markers

KW - Nitroimidazole markers

KW - Sampling error

UR - http://www.scopus.com/inward/record.url?scp=0030788550&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030788550&partnerID=8YFLogxK

U2 - 10.1016/S0167-8140(97)01931-2

DO - 10.1016/S0167-8140(97)01931-2

M3 - Article

C2 - 9288846

AN - SCOPUS:0030788550

VL - 44

SP - 171

EP - 176

JO - Radiotherapy and Oncology

JF - Radiotherapy and Oncology

SN - 0167-8140

IS - 2

ER -